Bavarian Nordic A/S buy BiotechBee
Start price
19.08.24
/
50%
€41.01
Target price
31.08.26
€50.00
Performance (%)
-13.09%
Price
15:19
€35.64
Summary
This prediction is currently active. The prediction for Bavarian Nordic A/S disappoints with a performance of -13.09%. This prediction currently runs until 31.08.26. The prediction end date can be changed by BiotechBee at any time. BiotechBee has 50% into this predictionBavarian Nordic (symbol: BAVA) is a biotechnology company that specializes in developing innovative vaccines for serious diseases such as cancer and infectious diseases like Ebola and COVID-19. The company has a broad portfolio of vaccines that are under development and has collaboration agreements with various pharmaceutical companies and government agencies. Bavarian Nordic's flagship product is its cancer vaccine known as PROSTVAC, which is currently undergoing clinical trials for the treatment of prostate cancer. The company is listed on the NASDAQ Copenhagen stock exchange and has a market capitalization of approximately $925 million as of May 2021.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Bavarian Nordic A/S | -0.600% |
| iShares Core DAX® | 2.147% |
| iShares Nasdaq 100 | -0.578% |
| iShares Nikkei 225® | 0.635% |
| iShares S&P 500 | 0.746% |
According to BiotechBee what are the pros and cons of Bavarian Nordic A/S for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by BiotechBee for this prediction
In the thread Bavarian Nordic A/S diskutieren
Buy mit Kursziel 50,0